VYNE
Price:
$0.3742
Market Cap:
$6.24M
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo...[Read more]
Industry
Biotechnology
IPO Date
2018-01-25
Stock Exchange
NASDAQ
Ticker
VYNE
According to VYNE Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.47. This represents a change of -77.83% compared to the average of -2.12 of the last 4 quarters.
The mean historical PE Ratio of VYNE Therapeutics Inc. over the last ten years is -14.69. The current -0.47 PE Ratio has changed 220.04% with respect to the historical average. Over the past ten years (40 quarters), VYNE's PE Ratio was at its highest in in the March 2022 quarter at 1.93. The PE Ratio was at its lowest in in the September 2016 quarter at -48.54.
Average
-14.69
Median
-1.99
Minimum
-71.89
Maximum
-0.25
Discovering the peaks and valleys of VYNE Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 325.74%
Maximum Annual PE Ratio = -0.25
Minimum Annual Increase = -91.47%
Minimum Annual PE Ratio = -71.89
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -3.58 | 325.74% |
| 2023 | -0.84 | 231.98% |
| 2022 | -0.25 | -64.60% |
| 2021 | -0.72 | -10.71% |
| 2020 | -0.80 | -64.13% |
| 2019 | -2.23 | 28.79% |
| 2018 | -1.74 | -91.47% |
| 2017 | -20.34 | -54.26% |
| 2016 | -44.46 | -38.16% |
The current PE Ratio of VYNE Therapeutics Inc. (VYNE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.56
5-year avg
-1.24
10-year avg
-14.69
VYNE Therapeutics Inc.’s PE Ratio is less than AIM ImmunoTech Inc. (-0.20), less than KALA BIO, Inc. (-0.19), less than Pasithea Therapeutics Corp. (-0.00), greater than Soligenix, Inc. (-0.50), greater than Alaunos Therapeutics, Inc. (-1947.11), less than Brainstorm Cell Therapeutics Inc. (-0.46), greater than Quoin Pharmaceuticals, Ltd. (-0.91), less than Ensysce Biosciences, Inc. (-0.43), greater than XTL Biopharmaceuticals Ltd. (-4.14), less than Matinas BioPharma Holdings, Inc. (-0.23),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.20 | $4.19M | |
| -0.19 | $6.77M | |
| -0.00 | $8.63M | |
| -0.50 | $16.43M | |
| -1947.11 | $8.01M | |
| -0.46 | $6.73M | |
| -0.91 | $11.12M | |
| -0.43 | $3.86M | |
| -4.14 | $4.76M | |
| -0.23 | $4.17M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like VYNE Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like VYNE Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is VYNE Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for VYNE Therapeutics Inc. (VYNE)?
What is the highest PE Ratio for VYNE Therapeutics Inc. (VYNE)?
What is the 3-year average PE Ratio for VYNE Therapeutics Inc. (VYNE)?
What is the 5-year average PE Ratio for VYNE Therapeutics Inc. (VYNE)?
How does the current PE Ratio for VYNE Therapeutics Inc. (VYNE) compare to its historical average?